Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
VASC's Cash to Debt is ranked higher than
87% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. VASC: No Debt )
VASC' s 10-Year Cash to Debt Range
Min: 1.11   Max: No Debt
Current: No Debt

Equity to Asset 0.88
VASC's Equity to Asset is ranked higher than
92% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. VASC: 0.88 )
VASC' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.96
Current: 0.88

0.34
0.96
Interest Coverage 1238.23
VASC's Interest Coverage is ranked higher than
68% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 235.10 vs. VASC: 1238.23 )
VASC' s 10-Year Interest Coverage Range
Min: 48.63   Max: 9999.99
Current: 1238.23

48.63
9999.99
F-Score: 5
Z-Score: 20.79
M-Score: -2.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 15.91
VASC's Operating margin (%) is ranked higher than
90% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. VASC: 15.91 )
VASC' s 10-Year Operating margin (%) Range
Min: -1096.15   Max: 17.33
Current: 15.91

-1096.15
17.33
Net-margin (%) 9.96
VASC's Net-margin (%) is ranked higher than
85% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. VASC: 9.96 )
VASC' s 10-Year Net-margin (%) Range
Min: -1040.69   Max: 27.25
Current: 9.96

-1040.69
27.25
ROE (%) 12.15
VASC's ROE (%) is ranked higher than
86% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. VASC: 12.15 )
VASC' s 10-Year ROE (%) Range
Min: -72.4   Max: 72.44
Current: 12.15

-72.4
72.44
ROA (%) 10.74
VASC's ROA (%) is ranked higher than
91% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. VASC: 10.74 )
VASC' s 10-Year ROA (%) Range
Min: -67.48   Max: 42.87
Current: 10.74

-67.48
42.87
ROC (Joel Greenblatt) (%) 44.25
VASC's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. VASC: 44.25 )
VASC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2404.09   Max: 56.56
Current: 44.25

-2404.09
56.56
Revenue Growth (3Y)(%) 12.10
VASC's Revenue Growth (3Y)(%) is ranked higher than
87% of the 340 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. VASC: 12.10 )
VASC' s 10-Year Revenue Growth (3Y)(%) Range
Min: 8.5   Max: 91.3
Current: 12.1

8.5
91.3
EBITDA Growth (3Y)(%) 9.60
VASC's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. VASC: 9.60 )
VASC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -65.2   Max: 207.2
Current: 9.6

-65.2
207.2
EPS Growth (3Y)(%) -19.80
VASC's EPS Growth (3Y)(%) is ranked higher than
64% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. VASC: -19.80 )
VASC' s 10-Year EPS Growth (3Y)(%) Range
Min: -67.2   Max: 22.1
Current: -19.8

-67.2
22.1
» VASC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

VASC Guru Trades in Q4 2013

Chuck Royce 52,000 sh (+1344.44%)
Bill Frels 118,621 sh (+57.58%)
Jim Simons 271,100 sh (+15.46%)
Mario Gabelli 301,171 sh (-1.79%)
» More
Q1 2014

VASC Guru Trades in Q1 2014

Joel Greenblatt 24,570 sh (New)
Chuck Royce 141,245 sh (+171.63%)
Bill Frels 134,821 sh (+13.66%)
Jim Simons 302,300 sh (+11.51%)
Mario Gabelli 284,071 sh (-5.68%)
» More
Q2 2014

VASC Guru Trades in Q2 2014

Jim Simons 386,706 sh (+27.92%)
Bill Frels 164,121 sh (+21.73%)
Chuck Royce 171,400 sh (+21.35%)
Mario Gabelli 266,771 sh (-6.09%)
Joel Greenblatt 19,877 sh (-19.1%)
» More
Q3 2014

VASC Guru Trades in Q3 2014

Chuck Royce 171,400 sh (unchged)
Mario Gabelli 266,771 sh (unchged)
Joel Greenblatt Sold Out
Bill Frels 161,170 sh (-1.8%)
Jim Simons 352,000 sh (-8.97%)
» More
» Details

Insider Trades

Latest Guru Trades with VASC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Sold Out 0.01%$21.87 - $25.07 $ 27.315%0
Joel Greenblatt 2014-03-31 New Buy0.01%$22.99 - $26.92 $ 27.310%24570
Joel Greenblatt 2013-03-31 Sold Out 0.01%$14.4 - $16.71 $ 27.375%0
Joel Greenblatt 2012-12-31 New Buy0.01%$13.32 - $15.35 $ 27.387%10137
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 39.40
VASC's P/E(ttm) is ranked higher than
80% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 84.60 vs. VASC: 39.40 )
VASC' s 10-Year P/E(ttm) Range
Min: 5.15   Max: 688.46
Current: 39.4

5.15
688.46
P/B 4.35
VASC's P/B is ranked higher than
68% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. VASC: 4.35 )
VASC' s 10-Year P/B Range
Min: 2.37   Max: 17.18
Current: 4.35

2.37
17.18
P/S 3.95
VASC's P/S is ranked higher than
68% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. VASC: 3.95 )
VASC' s 10-Year P/S Range
Min: 1.37   Max: 12.36
Current: 3.95

1.37
12.36
PFCF 31.02
VASC's PFCF is ranked higher than
87% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VASC: 31.02 )
VASC' s 10-Year PFCF Range
Min: 10.72   Max: 53.46
Current: 31.02

10.72
53.46
EV-to-EBIT 22.08
VASC's EV-to-EBIT is ranked higher than
84% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 61.55 vs. VASC: 22.08 )
VASC' s 10-Year EV-to-EBIT Range
Min: -485.1   Max: 387
Current: 22.08

-485.1
387
PEG 2.11
VASC's PEG is ranked higher than
95% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VASC: 2.11 )
VASC' s 10-Year PEG Range
Min: 0.45   Max: 2.98
Current: 2.11

0.45
2.98
Shiller P/E 32.01
VASC's Shiller P/E is ranked higher than
90% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VASC: 32.01 )
VASC' s 10-Year Shiller P/E Range
Min: 19.15   Max: 149.17
Current: 32.01

19.15
149.17
Current Ratio 5.89
VASC's Current Ratio is ranked higher than
89% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. VASC: 5.89 )
VASC' s 10-Year Current Ratio Range
Min: 1.94   Max: 26.32
Current: 5.89

1.94
26.32
Quick Ratio 4.78
VASC's Quick Ratio is ranked higher than
87% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. VASC: 4.78 )
VASC' s 10-Year Quick Ratio Range
Min: 1.36   Max: 25.52
Current: 4.78

1.36
25.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 17.73
VASC's Price/Net Cash is ranked higher than
88% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VASC: 17.73 )
VASC' s 10-Year Price/Net Cash Range
Min: 0.59   Max: 539.5
Current: 17.73

0.59
539.5
Price/Net Current Asset Value 10.11
VASC's Price/Net Current Asset Value is ranked higher than
86% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VASC: 10.11 )
VASC' s 10-Year Price/Net Current Asset Value Range
Min: 0.54   Max: 38.24
Current: 10.11

0.54
38.24
Price/Tangible Book 5.40
VASC's Price/Tangible Book is ranked higher than
74% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 6.92 vs. VASC: 5.40 )
VASC' s 10-Year Price/Tangible Book Range
Min: 0.49   Max: 16.68
Current: 5.4

0.49
16.68
Price/DCF (Projected) 1.95
VASC's Price/DCF (Projected) is ranked higher than
89% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VASC: 1.95 )
VASC' s 10-Year Price/DCF (Projected) Range
Min: 1.34   Max: 130.33
Current: 1.95

1.34
130.33
Price/Median PS Value 1.49
VASC's Price/Median PS Value is ranked higher than
64% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. VASC: 1.49 )
VASC' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 12.67
Current: 1.49

0.31
12.67
Price/Peter Lynch Fair Value 2.71
VASC's Price/Peter Lynch Fair Value is ranked higher than
95% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VASC: 2.71 )
VASC' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.23   Max: 8.67
Current: 2.71

0.23
8.67
Price/Graham Number 3.04
VASC's Price/Graham Number is ranked higher than
83% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. VASC: 3.04 )
VASC' s 10-Year Price/Graham Number Range
Min: 0.89   Max: 10.83
Current: 3.04

0.89
10.83
Earnings Yield (Greenblatt) 4.50
VASC's Earnings Yield (Greenblatt) is ranked higher than
83% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. VASC: 4.50 )
VASC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 10.3
Current: 4.5

0.3
10.3
Forward Rate of Return (Yacktman) 17.12
VASC's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 5.52 vs. VASC: 17.12 )
VASC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -57.3   Max: 54.1
Current: 17.12

-57.3
54.1

Business Description

Industry: Medical Devices » Medical Devices
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:VA4.Germany,
Vascular Solutions Inc was incorporated in the state of Minnesota in December 1996. It is a medical device company, creates new minimally invasive medical devices, and delivers these products and related services to physicians through its direct domestic sales force and its international distribution network. The Companys products and services are divided into three categories: Catheter products; Hemostat products and Vein products and services. Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner catheter used to access discrete regions of the coronary anatomy and the Pronto extraction catheters used in treating acute myocardial infarction. Hemostat products consist principally of blood clotting products, such as the D-Stat Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets. Vein products and services consist principally of the Vari-Lase endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter. The Company manufactures its products in its facilities located in the suburbs of Minneapolis, Minnesota and in the country of Ireland. The catheter manufacturing and packaging processes occur under a controlled clean room environment. It purchases components from various suppliers and rely on single sources for several parts of its products. It purchases its requirements for thrombin for use in manufacturing products sold in the U.S. under the Thrombin-JMI Supply Agreement with King. Its main competitors include: Medtronic, Boston Scientific, Covidien, Merit Medical, Marine Polymer Technologies, Cook Medical, Spectranetics, AngioDynamics and Terumo. The Companys products and services are regulated in the United States as medical devices by the FDA under the Federal Food, Drug and Cosmetic Act.
» More Articles for VASC

Headlines

Articles On GuruFocus.com
Vascular Solutions Inc. Reports Operating Results (10-K) Feb 01 2011 
Vascular Solutions Inc. (VASC) CEO Howard Root sells 25,000 Shares Nov 04 2010 
Vascular Solutions Inc. Reports Operating Results (10-K) Feb 02 2010 
Vascular Solutions Inc. Reports Operating Results (10-Q) Apr 17 2009 
Vascular Solutions, Inc. to Webcast Fourth Quarter Conference Call Tuesday, February 3, 2009 at 3:30 Jan 08 2009 

More From Other Websites
Vascular Solutions Announces FDA 510(K) Clearance of ZigiWire™ Access Guidewire System Dec 19 2014
Vascular Solutions Announces FDA 510(k) Clearance of ZigiWire(TM) Access Guidewire System Dec 19 2014
Vascular Solutions Announces FDA 510(k) Clearance of VSI Radial Introducer Sheath Dec 08 2014
Vascular Solutions Announces FDA 510(k) Clearance of VSI Radial Introducer Sheath Dec 08 2014
Vascular Solutions Completes Purchase of Principal Manufacturing Facility Dec 02 2014
Vascular Solutions Completes Purchase of Principal Manufacturing Facility Dec 02 2014
Vascular Solutions Receives 510(K) Clearance for Turnpike™ Catheters Dec 01 2014
Vascular Solutions Receives 510(k) Clearance for Turnpike(TM) Catheters Dec 01 2014
Vascular Solutions Receives 510(K) Clearance for Gel-Block™ 10x Embolization Product Dec 01 2014
Lifshitz & Miller Law Firm Announces Investigation of FireEye, Inc., Hanger Inc., Hertz Global... Nov 25 2014
Vascular Solutions Receives 510(k) Clearance for Gel-Block(TM) 10x Embolization Product Nov 25 2014
Robbins Arroyo LLP Is Investigating the Officers and Directors of Vascular Solutions, Inc. (VASC) on... Nov 20 2014
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Nov 19 2014
APNewsBreak: Vascular Solutions subsidy scrapped Nov 19 2014
APNewsBreak: Vascular Solutions subsidy scrapped Nov 19 2014
Vascular Solutions Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into... Nov 19 2014
Vascular Solutions to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 18 2014
Vascular Solutions to Present at the Canaccord Genuity Medical Technology and Diagnostics Forum Nov 17 2014
Vascular Solutions to Present at the Canaccord Genuity Medical Technology and Diagnostics Forum Nov 17 2014
Weakness Seen in Vascular Solutions (VASC): Stock Plunges 22.2% Nov 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK